Academic literature on the topic 'Pharmacoépidémiologie – France'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmacoépidémiologie – France.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Pharmacoépidémiologie – France":
Martin, K., P. Latry, Y. Moride, and B. Bégaud. "Où trouver des données pour la pharmacoépidémiologie en France? Quelques idées." Revue d'Épidémiologie et de Santé Publique 55, no. 1 (February 2007): 58–63. http://dx.doi.org/10.1016/j.respe.2007.01.001.
Bertin, P., P. Goupille, F. Tubach, E. Lespessailles, N. Harid, S. Sequeira, J. M. Fayette, B. Fautrel, and R. M. Flipo. "FRI0274 HISTORY OF BIOLOGICS AND FEMALE GENDER ARE LINKED TO GOLIMUMAB DISCONTINUATION IN AXIAL SPONDYLOARTHRITIS: A SUB-ANALYSIS OF THE GO-PRACTICE STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 723–24. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3025.
Piedbois, P., F. Thomas-Delecourt, and A. Flinois. "Étude pharmacoépidémiologique sur l'utilisation de fulvestrant en pratique clinique en France." Bulletin du Cancer 96, no. 6 (June 2009): 695–702. http://dx.doi.org/10.1684/bdc.2009.0876.
Seror, R., B. Fautrel, A. Lafourcade, Y. De-Rycke, X. Mariette, and F. Tubach. "OP0124 RISK OF MALIGNANCIES ACROSS BIOLOGIC CLASSES IN RHEUMATOID ARTHRITIS: ANALYSIS OF A NATIONAL CLAIM DATABASE." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 81.2–82. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3687.
Seror, R., A. Lafourcade, Y. De-Rycke, B. Fautrel, X. Mariette, and F. Tubach. "THU0151 RISK OF MALIGNANCIES ASSOCIATED WITH CS DMARDS IN RHEUMATOID ARTHRITIS: COMPARISON WITH GENERAL POPULATION AND BIOLOGIC TREATED PATIENTS (ANALYSIS OF A NATIONAL CLAIM DATABASE)." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 291.1–291. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3656.
Gully, M., E. Frauger, M. Spadari, V. Pauly, F. Romain, S. Burtey, M. Sallée, et al. "Effets uronéphrologiques des produits utilisés par les usagers de drogues : revue de la littérature et enquête pharmacoépidémiologique en France et dans la région de Marseille." Néphrologie & Thérapeutique 13, no. 5 (September 2017): 376–77. http://dx.doi.org/10.1016/j.nephro.2017.08.258.
Duru, Gérard, Jean Vetel, and Karine Danno. "Management of Anxiety and Depressive Disorders in Patients ≥ 65 Years of Age by Homeopath General Practitioners versus Conventional General Practitioners, with Overview of the EPI3-LASER Study Results." Homeopathy 107, no. 02 (March 20, 2018): 081–89. http://dx.doi.org/10.1055/s-0038-1636536.
Dissertations / Theses on the topic "Pharmacoépidémiologie – France":
Conte, Cécile. "Evaluation des consommations médicamenteuses associées au décours d'un lymphome : approche pharmacoépidémiologique." Thesis, Toulouse 3, 2018. http://www.theses.fr/2018TOU30185/document.
This thesis presents a pharmacoepidemiology approach to describe drug utilization in lymphomas during their whole care pathway. The use of the French claims database (Système National d'Informations Inter-Régimes de l'Assurance Maladie (SNIIRAM)) allows to exhaustively quantify this drug utilization in real life conditions. This thesis consists of three mains objectives. First, we aimed to develop validated algorithms for the identification of incident cases of lymphoma. For the validation, we used data from a regional Cancer Registry as the gold standard. The purpose of this validation study was to enhance validity of future studies conducted on lymphomas in the SNIIRAM database. The results of this study associated to strengths of this database demonstrate that this approach is of great interest to conduct pharmacoepidemiological or medico-economic studies in lymphomas. Second, we aimed to estimate the incidence of use of psychotropic drugs during the active treatment phase of lymphoma in comparison with control groups. Indeed, the increased probability of developing anxio-depressive disorders after diagnosis could lead to an increased initiation of psychotropic drugs and a potential inappropriate chronic use of these drugs after initiation. Such inappropriate chronic use can unnecessarily expose patients to adverse event. For this aim, we conducted a new-user cohort study using data from the SNIIRAM database. The results of this study revealed that the initiation rate of these drugs is higher than in the general population or for life-threatening diseases such as myocardial infarction. Moreover, we observed an inappropriate prolonged use for a significant fraction of patients (20% to more than 50% according to therapeutic class). On the basis of these findings, the third objective was to identify factors associated with prolonged use of these drugs during survivorship. This study was conducted using data from the General Sample of Beneficiaries (EGB). [...]
Moulis, Guillaume. "Pharmacoépidémiologie de la thrombopénie immunologique en France : suivi de cohorte issue du Système national d'information inter-régimes de l'Assurance maladie et création d'un registre clinique." Thesis, Toulouse 3, 2016. http://www.theses.fr/2016TOU30005/document.
Immune thrombocytopenia (ITP) is a rare autoimmune bleeding disorder. ITP epidemiology is not well known. ITP treatment is based on glucocorticoids, and intravenous polyvalent immunoglobulin in case of severe bleeding. ITP becomes persistent (lasting more than 3 months) or chronic (more than 12 months) in about 70% of adults. In that case, non-corticosteroid treatments are suggested, mostly splenectomy, rituximab and thrombopoietin receptor agonists. The use of these treatments have never been assessed in the real life practice as well as their effectiveness and safety, particularly as regards the risk of infection. Vaccinations are recommended before splenectomy or rituximab. However, the vaccination rates and their effectiveness has not been assessed. We build two complementary materials: 1) the French Adult Immune Thrombocytopenia: a pHarmacoepidemiological study (FAITH) is the cohort of all incident primary ITP adults persistently treated (more than 3 months), built in the French health Insurance system database (Système national d'information inter-régimes de l'Assurance Maladie, SNIIRAM) at the national level; 2) the Cytopénie Auto-immune : Registre Midi-PyrénéEN (CARMEN) registry that includes and follows all incident ITP adults in the French Midi-Pyrénées region. Thanks to these two cohorts, we could assess the epidemiology of incident ITP in France; describe the exposure ITP treatments; assess the vaccination coverage in rituximab treated and splenectomized patients in France; and assess the risk of infection according to ITP treatments and the protective effect of the vaccines in this population
Bosco-Lévy, Pauline. "Heart failure in France : chronic heart failure therapeutic management and risk of cardiac decompensation in real-life setting." Thesis, Bordeaux, 2019. http://www.theses.fr/2019BORD0348.
In France, around one million persons would be affected by heart failure (HF); there are nearly 70 000 deaths related to HF and more than 150 000 hospitalizations despite a well defined treatment management. These numbers should increase in the next years due in particular to the ageing of the population.The objective of this work was to study the use of the pharmacological treatments indicated in HF (beta-blocker, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone antagonist, diuretics, digoxin, ivabradine) in real-world setting and to identify the clinical or pharmacological predictors associated with a new episode of cardiac decompensation.A first work has enabled to estimate the accuracy of French claims databases in identifying HF patients.A second study estimated that 17 to 37% HF patients were not exposed to any HF treatment in the year following an incident HF hospitalization.The third and fourth parts of this thesis showed that almost one forth of HF patients was rehospitalized within the 2 years following a first hospitalization. The main clinical predictors of rehospitalization were age, high blood pressure, atrial fibrillation and diabetes. The association found between bivalent iron use and HF rehospitalization underlines the importance of the risk related to anemia or iron deficiency in the occurrence of a cardiac exacerbation episode.These results allow to reconsider the treatment management of HF patients and highlight the need to reinforce the surveillance of patients with a highest risk of cardiac exacerbation
Demesmaeker, Alice. "La morbi-mortalité par suicide : de l'épidémiologie longitudinale à l'évaluation d'un dispositif de prévention." Electronic Thesis or Diss., Université de Lille (2022-....), 2023. http://www.theses.fr/2023ULILS014.
Patients with a psychiatric disorder have a decreased life expectancy associated with a high rate of suicide and non-psychiatric diseases. In addition, patients who have attempted suicide (SA) are at particular risk for re-attempt and premature death. First, we tried to identify risk factors for re-attempt with novel statistical approaches. Thus, patients with an alcohol use disorder and with an acute alcohol use during their SA, patients with an anxiety disorder, those who had more than 2 SAs and those who consumed benzodiazepines and/or hypnotics had a high risk of re-attempt.Then, we estimated the rate of death by suicide after SA using a meta-analysis. Our results showed a rate of 2.8% at 1 year. Then, we searched for causes of death in the Vigilans cohort. One year after SA, the most common causes of death were suicide and cardiovascular diseases.Finally, we showed an example of an assessment of a suicide prevention program. We evaluated the effectiveness of training gatekeepers in nursing homes. Our results showed an improvement in knowledge about the suicidal crisis and a decrease in the number of SAs after the training.In conclusion, the reduction of the morbidity and mortality of those who have attempted suicide requires a global management: by suicide prevention, but also by the management of non-psychiatric diseases
Chenaf, Chouki. "Approche pharmaco-épidémiologique de la douleur chronique neuropathique en France et évaluation d'une nouvelle stratégie thérapeutique : intérêt de l'agomélatine." Thesis, Université Clermont Auvergne (2017-2020), 2019. http://www.theses.fr/2019CLFAS026.
Chronic pain is a major and complex problem, which has a profound impact on individuals by altering their functional and emotional capacities as well as their quality of life. According to new IASP terminology adopted in 2017, three types of chronic pain are identified: nociceptive, nociplastic, and neuropathic. In particular, neuropathic pain, defined as pain related to an injury or disease affecting the somatosensory system, is the subject of three major issues: 1/ the need for a better knowledge of its epidemiology, which must be based on a standardisation of the definitions and tools used, as current estimates remain very heterogeneous, 2/ the need to evaluate in real-life the use, efficacy and adequacy of drug therapies with the latest recommendations, in order to optimize the quality of neuropathic pain management with a view to better treatment personalization and 3/ the urgency to develop new, more effective and better tolerated therapeutic strategies, neuropathic pain being widely recognized as one of the most difficult painful syndromes to manage optimally. The first part of this work focused on updating French epidemiological data on the prevalence of chronic pain with or without neuropathic characteristics by using for the first time in this theme the capture-recapture method, based on the use of EGB database: in 2015, the prevalence of chronic pain with or without neuropathic characteristics in the general French adult population was estimated at 27.2% [CI 95%: 26.1-28.4] and chronic neuropathic pain at 7.20% [CI 95%: 6.38-8.22]. This method has demonstrated its major interest, given not only the speed and reliability of the estimates obtained, but also the ease of its implementation and its lower cost compared to conventional studies or field surveys, while getting rid from the traditional limits of the latter in terms of representativeness and generalizability.The second part of our work proposed to carry out a pharmaco-epidemiological evaluation of the real-life use of recommended treatments in neuropathic pain and their persistence in a cohort of incident painful neuropathic patients, based on the use of the SNIIRAM database. Between January 2013 and December 2016, 29 756 incident patients were identified and less than half of them (44.1%) had received a recommended first-line treatment as monotherapy, and approximately one third of patients (32.8%) received a first prescription corresponding to a combination of at least two recommended molecules. Finally, less than half of patients (46.3%) were still treated with at least one of the recommended drugs at 1 year and about one-third (33.5%) were still treated at 2 years; persistence to the recommended treatments was lower in patients treated with monotherapy and in those with neuropathic cancer pain, but better in patients with depression.Finally, in a third preclinical section, we evaluated the analgesic potential of agomelatine, an antidepressant marketed a few years ago (VALDOXAN®) whose original pharmacodynamic mechanism is based on agonist activity at the MT1/MT2 melatoninergic receptors and antagonist at the 5-HT2C receptors. Agomelatine reduced dose-dependently the hyperalgesia induced in three animal models of neuropathic pain, both after single and repeated administration, without tachyphylaxis or tolerance, with an efficacy at least equal to that of gabapentin. This effect was exerted through the spinal involvement of melatoninergic receptors, α-2 adrenergic and serotoninergic 5-HT2C, without involvement of ß-adrenergic receptors. Finally, an isobolographic analysis concluded that the combination of agomelatine and gabapentin was additive. In conclusion, this work demonstrated the major interest of using Health Insurance database to address pharmaco-epidemiological issues in neuropathic pain and offered a new and interesting therapeutic perspective through agomelatin in optimizing the management of neuropathic pain
Etchepare, Fanny. "Etude du respect des recommandations de prescription et d'utilisation des médicaments psychotropes chez les sujets âgés en France." Thesis, Bordeaux, 2015. http://www.theses.fr/2015BORD0200/document.
Despite a high frequency of use and a tendency to present with adverse events of drugs, few studies assessed compliance with guidelines related to proper use of psychotropic drugs in the older population. The aim was to assess the patterns of psychotropic drugs use in this population, as well as the compliance with French guidelines. Two population samples were included, a clinical sample of older psychiatric inpatients and a sample of the older general population using claims database of the national health insurance. In clinical population, compliance with guidelines was rather good, with prescription of a short half-life benzodiazepine in nearly three quarters of prescriptions and adequate dosage in nearly two third of cases. However, treatment discontinuation was never specified at the time of treatment initiation and rhythm of prescription was discontinuous in only one third of cases. In the older general population, duration of antidepressant treatment and biological monitoring was appropriate in only 20 % of patients, whereas nearly three quarters of subjects initiating a benzodiazepine treatment were treated over an appropriate duration. However, less than half of them had received a benzodiazepine anxiolytic of short half-life. The assessment of the impact of practice guidelines publication found no improvement of psychotropic drugs use. Other interventions should accompany guidelines publication in order to underline the importance of proper use of drugs, particularly antidepressant treatment duration and use of short half-life benzodiazepine drugs
Doat, Solène. "Rôle de la consommation d'Anti-inflammatoires Non Stéroïdiens (AINS) dans la survenue du cancer de la prostate, du sein, et colorectal en France." Thesis, Université Paris-Saclay (ComUE), 2017. http://www.theses.fr/2017SACLS550/document.
Background – Prostate, breast, and colorectal cancers are among the most common cancers in developed countries. Many risk factors have been identified over the years but could explain only a part of the new cases. Chronic inflammation is highly suspected to play a role in the carcinogenesis of those cancers and the presence of inflammatory infiltrate in tumoral tissue, considered as precancerous lesions, reinforced this hypothesis. In this context, several epidemiological studies have investigated the potential role of Non-steroidal anti-inflammatory drugs (NSAIDs) in cancer occurrence. Indeed, NSAIDs such as aspirin and non-aspirin NSAIDS including selective inhibitors of cyclo-oxygenase 2 (COX-2) may decrease the incidence of those cancers.Objectives – The main objective of the thesis was to investigate the role of NSAIDs use including aspirin, non-aspirin NSAIDs and selective inhibitors of COX-2 in the occurrence of prostate, breast and colorectal cancers.Population and methods – This work was based on the General Sample of health insurance Beneficiaries (EGB) for the three localizations of cancer and on the data of a population-based case-control study carried out in the département of Herault (EPICAP) for prostate cancer. In the EGB study, a cohort of 426 410 persons present in the database in January 1st, 2007 allowed to identify incident cases between 2008 and 2012 based on different algorithms. Exposure to NSAIDs was determined from January 1st, 2005 until the end of the follow up defined as either cancer incident date, date of death, or censure date fixed as December 31st, 2012. A latency of at least one year between the beginning of exposure to NSAIDs and the cancer occurrence was taken into account. For the EPICAP study, 819 incident prostate cancer cases and 879 population-based controls, frequently matched by age to the cases, were face-to-face interviewed using a standardized questionnaire, specifically on their NSAIDs use.Results – From the EGB cohort, preliminary results showed a positive association between all NSAIDs use and prostate or breast cancer occurrence (RR=1,30 [1,17-1,46], RR=1,29 [1,14-1,46], respectively), while no association was found with colorectal cancer occurrence (RR=0,92 [0,82-1,05]). These associations became negative associations when a latency of six years was taken into account in prostate and colorectal cancer (RR=0,85[0,74-0,96], RR=0,77 [0,66-0,90], respectively). In the EPICAP study, NSAIDs use was negatively associated with prostate cancer (OR=0,77 [0,61-0,98]). This association was more pronounced with daily intake (OR=0,75 [0,33-0,92]) or more than once a day (OR=0,38 [0,18-0,79]), and for a duration of five to ten years (OR=0,55 [0,33-0,92]). The negative association was reinforced for preferential anti-COX-2 NSAIDs (OR=0,48 [0,28-0,79]), and for patient with high grade prostate cancer (Gleason score, GS=7 (4+3) or GS>7 : OR=0,62 [0,41-0,95]).Conclusion – This work showed that NSAIDs use was negatively to prostate and colorectal cancer occurrence. For prostate cancer, this thesis was based on two different databases (a medical and administrative database and a case-control study) and used two different methodologies, allowing comparison about strengths and limits of both
Blotière, Pierre-Olivier. "Utilisation des bases de données de l’Assurance Maladie pour l’étude de l’utilisation des antiépileptiques pendant la grossesse et des risques associés à l’exposition in utero chez l’enfant." Thesis, Université de Lorraine, 2019. http://www.theses.fr/2019LORR0053.
The works of this thesis have been carried out within a programme of pharmacoepidemiological studies initiated by the National Agency of Medicine and Health Product Safety (ANSM) and the National Health Insurance fund (Cnam) in order to evaluate the public health situation in relation to prenatal exposure to valproic acid in France on the basis of the French health care databases. The objective of this thesis was to study antiepileptic drug (AED) use during pregnancy and the risks of congenital malformations and neurodevelopmental disorders associated with prenatal exposure to these drugs. In a first study, we developed an algorithm to identify pregnancy episodes and related outcomes using the French health care claims databases and applied it to study AED use during pregnancy between 2007 and 2014. Over the study period, 6.7 per 1000 pregnancies were exposed to an AED. The use of newer AEDs increased concomitantly with the decreased use of valproic acid and the other older AEDs. In a second study, prenatal exposure to valproic acid was found to be associated with a wide range of malformations among those investigated, with a dose-response relationship for half of them, and prenatal exposure to topiramate with an increased risk of cleft lip with or without cleft palate. Signals concerning pregabalin, clonazepam and phenobarbital have also been identified. In a third study, prenatal exposure to valproic acid was found to be associated with increased risks of all early neurodevelopmental outcomes investigated compared with lamotrigine, with a dose-response relationship. Prenatal exposure to the other AEDs was not associated with an increased risk of any of these neurodevelopmental outcomes versus lamotrigine. Conducting pharmacoepidemiological studies based on the French health care databases enabled the health authorities to rapidly provide data on the use of AED during pregnancy in France. It also brought additional evidence to the international observational literature on the consequences of prenatal exposure to AEDs for the unborn child